Abstract
Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality worldwide. Basic fibroblast growth factor (bFGF) is up-regulated in NSCLC patients and plays an important role in tumor growth and angiogenesis. Therefore, it is regarded as a potential therapeutic target of NSCLC. We have previously obtained a high-affinity bFGF antagonist peptide (named P7) with the potential of suppressing angiogenesis stimulated by bFGF from the phage display random heptapeptide library. Herein, we further revealed the underlying anti-angiogenic mechanisms of P7 peptides in human NSCLC cells. P7 not only inhibited the expressions of angiogenesis related factors including VEGF, MMP-2 and MMP-9 at both transcriptional and translational levels, but also induced significant changes in the expressions of proteins related to tumor growth and progress. Our results suggested that P7 peptides with potent anti-angiogenic activity may have therapeutic potential in NSCLC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Peptide Research and Therapeutics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
